2637 E Atlantic Blvd #43110
Pompano Beach, FL 33062
5th International Academic Conference on Medical and Health Sciences Vennue: Patra Jasa Bali Resort & Villas Jl.Ir. H Juanda, South Kuta Beach, Kuta 80361, Bali-Indonesia Date: 07-Jul-2018 More Details
49th International Scientific Conference on Sport, Medical and Health Sciences Vennue: Hotel Istana Kuala Lumpur City Centre 73 Jalan Raja Chulan, Kuala Lumpur, 50200, Malaysia Date: 04-Sep-2018 More Details
6th International Academic Conference on Medical and Health Sciences Vennue: Hotel Istana Kuala Lumpur City Centre 73 Jalan Raja Chulan, Kuala Lumpur, 50200, Malaysia Date: 08-Sep-2018 More Details
Background: Oral cancer is a one of the major health burden worldwide and also in India. The most strenuous problem in oral cancer is metastasis, where use of newer non-invasive biomarkers for early detection of metastatic tumors would be greatly helpful. Aim: The aim was to evaluate salivary matrix metalloproteinase-9 in patients with oral precancerous conditions (OPC) and oral cancer to assess its utility in monitoring oral cancer progression. Subjects and Methods: Total 250 subjects including 100 controls, 50 patients with OPC and 100 oral cancer patients were enrolled for the study. Gelatin zymography was performed for the evaluation of matrix metalloproteinase (MMP)-9 and truncated 42 kDa MMP. Statistical Analysis: Statistical analysis like Studentís independentĎtí test, Receiverís Operating Characteristic (ROC) curve, correlation and multivariate analysis were performed to analyze the results. Results: A truncated form of MMP i.e. 42 kDa was observed to have gelatinolytic activity. An increasing trend of salivary pro MMP-9, active MMP-9, MMP-9 activation ratio and truncated 42 kDa MMP was observed from controls to patients with OPC to oral cancer patients. ROC curve analysis revealed that all forms of MMPs could significantly discriminate controls and oral cancer patients; moreover, pro MMP-9 and active MMP-9 significantly distinguished patients with OPC and oral cancer patients. All the levels were found to be higher in patients with advanced disease and with metastasis as compared to patients with early disease and without metastasis, respectively. Conclusion: Elevated levels of salivary MMP-9 and truncated 42 kDa MMP in patients with OPC and oral cancer may be important for assessing early changes occurring during neoplastic transformation of oral cancer.
Z. Khan, "An overview of oral cancer in Indian subcontinent and recommendations to decrease its incidence," Webmed Central Cancer, vol. 3, pp. 1-29, 2012.
A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," CA Cancer J. Clin., vol. 61, pp. 69-90, 2011.
A. Gialeli, A. D. Theocharis, and N. K. Karamanaos, "Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting," FEBS J., vol. 278, pp. 16-27, 2011.
R. Roy, J. Yang, and M. Moses, "Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer," J. Clin. Oncol., vol. 27, pp. 5287-5297, 2009.
P. Vihenen and V. M. Kahari, "Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets," Int. J. Cancer, vol. 99, pp. 157-166, 2002.
M. H. Shah, R. N. Sainger, S. D. Telang, G. I. Pancholi, S. N. Shukla, and P. S. Patel, "E-cadherin and sialyl lewis-x overexpression in oral squamous cell carcinoma and oral precancerous conditions," Neoplasma, vol. 56, pp. 40-47, 2009.
B. P. Patel, P. M. Shah, U. M. Rawal, A. M. Desai, S. V. Shah, and R. M. Rawal, "Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma," J. Surg. Oncol., vol. 90, pp. 81-88, 2005.
R. D. Singh, H. Nilayangode, J. B. Patel, F. D. Shah, S. N. Shukla, and P. M. Shah, "Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer," Int. J. Biol. Markers, vol. 26, pp. 27-36, 2011.
R. D. Singh, N. Haridas, J. B. Patel, S. N. Shukla, P. M. Shah, and P. S. Patel, "Matrix metalloproteinases and their inhibitors: Correlation with invasion and metastasis in oral cancer," Indian J. Clin. Biochem., vol. 25, pp. 250-259, 2010.
R. C. Jordan, M. Macabeo-Ong, C. H. Shiboski, N. Dekker, D. G. Ginzinger, and D. T. Wong, "Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer," Clin. Cancer Res., vol. 10, pp. 6460-6465, 2004.
A. U. Nair, R. Thavarajah, and K. Ranganathan, "Saliva and dental practice," J. NTR Univ Health Sci., vol. 1, pp. 72-76, 2012.
D. T. W. Wong, "Salivaomics," J. Am. Dent. Assoc., vol. 143, pp. 19S-24S, 2012.
T. Pfaffe, J. Cooper-White, P. Beyerlien, K. Kostner, and C. Punyadeera, "Diagnostic potential of saliva: current state and future applications," Clin. Chem., vol. 57, pp. 675-87, 2011.
Y. Miyoshi, M. Watanabe, and N. Takahashi, "Autoactivation of proteolytic activity in human whole saliva," J. Oral Biosci., vol. 52, pp. 402-408, 2010.
F. I. Greene, D. L. Page, and I. D. Fleming, American joint committee on cancer (AJCC). Head and neck sites. In: Cancer staging manual, 6th ed. Philadelphia, PA: JB Lippincott, 2002.
S. Hu, J. Wang, J. Meijer, S. Ieong, Y. Xie, and T. Yu, "Salivary proteomic and genomic biomarkers for primary sjogrenís syndrome," Arthritis Rheum, vol. 56, pp. 3588-3600, 2007.
O. H. Lowry, N. J. Rosenbrough, A. L. Farr, and R. J. Randall, "Protein measurement with the folin phenol reagent," J. Biol. Chem., vol. 193, pp. 265-275, 1951.
J. A. Lorenzo, C. C. Pilbeam, J. F. Kalinowski, and M. S. Hibbs, "Production of both 92 kDa and 72 kDa gelatinases by bone cells," Matrix, vol. 12, pp. 282-289, 1992.
D. Peschos, C. Damala, D. Stefanou, E. Tsanou, D. Assimakopoulos, and T. Vougiouklakis, "Expression of matrix metalloproteinase -9 (Gelatinase B) in benign, premalignant and malignant laryngeal lesions," Histo. Histopathol., vol. 21, pp. 603-608, 2006.
R. P. Goncalves, C. A. Damante, F. L. S. Lima, A. V. Imbronito, F. D. Nunes, and F. E. Pustiglioni, "Detection of MMP-2 and MMP-9 salivary levels in patients with chronic periondontitis before and after periodontal treatment," Rev. Odonto Cienc., vol. 24, pp. 264-269, 2009.
T. Ingman, T. Sorsa, O. Lindy, H. Koski, and T. Konttinen, "Multiple forms of gelatinases /type IV collagenases in saliva and gingival crevicular fluid of periodontitis patients," J. Clin. Periodontal, vol. 21, pp. 26-31, 1994.
S. Triebel, J. Blaser, H. Relinke, and H. Tschesche, "A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase," FEBS Lett., vol. 314, pp. 386-388, 1992.
S. Y. Liu, M. H. Lin, S. C. Yang, G. C. Huang, L. Chang, and S. Chang, "Areca quid chewing enhances the expression of salivary matrix metalloproteinase-9," J. Formos Med. Assoc., vol. 104, pp. 113-119, 2005.
C. T. Chiu, C. Y. Chuang, S. W. Chang, S. Y. Lee, D. J. Wang, and Y. C. Liu, "Expression of matrix metalloproteinases in oral cancer patients who are betel quid users," Taiwan J. Oral Maxillofac. Surg., vol. 19, pp. 313-327, 2009.
S. D. Hong, S. P. Hong, J. I. Lee, and C. Y. Lim, "Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinoma with regard to the metastatic potential," Oral Oncol., vol. 36, pp. 207-213, 2000.